New research · August 2026
ABCL635 cuts hot flashes by 83% in 4 weeks, from a single injection.
AbCellera's investigational antibody drug just posted Phase 2 results that set a new benchmark for non-hormonal menopause treatment. Here's what it means, in plain language.
Key results at a glance
What the Phase 2 data showed
Hot flash frequency
83%
Mean reduction in moderate-to-severe hot flashes per day at week 4
Vs. placebo (frequency)
50%
Placebo-adjusted treatment difference (placebo reduced by 33%)
Hot flash severity
58%
Reduction in severity score at week 4, vs. 12% for placebo (p<0.001)
How the study worked: 92 postmenopausal women averaging ~10 moderate or severe hot flashes
per day were split 1:1. Half received a single 600 mg subcutaneous (under-the-skin) injection of ABCL635,
half received placebo. Results were measured weekly through 4 weeks. There were no serious adverse events and
no withdrawals due to side effects. The most common side effects were headache, fatigue, and injection site
reaction.
Why this matters: ABCL635 targets the NK3 receptor, the same brain signalling pathway as
fezolinetant and elinzanetant, but as an antibody rather than a pill. An antibody approach means it could
potentially work for months from a single dose. These Phase 2 results are described by the researchers as
"a new efficacy benchmark." Phase 3 would need to confirm this.
Full press release
Read the official results
Published August 10, 2026 by AbCellera Biologics Inc.
Could a menopause trial be right for you?
Research like this only happens because women volunteer to be part of it. See what menopause trials are recruiting near you right now. Free, private, no obligation.
The information on this page is based on a company press release and is for informational
purposes only. ABCL635 is an investigational drug and has not been approved by any
regulatory agency. This is not medical advice. Talk to your doctor before making any
decisions about your care.